Companies / Santa Cruz Biotechnology / GGPL-I (LI-77)
Santa Cruz Biotechnology

GGPL-I (LI-77) | Santa Cruz Biotechnology

mouse monoclonal IgM; GGPL-I Antibody (LI-77) is an IgM mouse monoclonal GGPL-I antibody (also designated GGPL-I antibody) that detects the GGPL-I protein of Mycoplasma fermentans origin by . GGPL-I Antibody (LI-77) is available as the non-conjugated anti-GGPL-I antibody. The genus Mycoplasma comprises the smallest organisms lacking cell walls that can self-replicate. Mycoplasma is attributed to various diseases in humans, including hematopoietic, joint, central nervous system, liver, pancreas and cardiovascular syndromes. Mycoplasma fermentans is present in human mucosal tissues, saliva and oropharyngeal of 45% of healthy adults. M. fermentans possesses a unique choline metabolic pathway that generates phosphocholine-containing glycoglycerolipids, 6'-O-phosphocholine-alpha-glucopyranosyl-(1′-3)-1,2-diacyl-sn- glycerol (GGPL-I) and 1′-phosphocholine,2′-amino dihydroxypropane-3′-phospho-6′-alpha-glucopyranosyl-(1′-3)-1,2-diacyl-glycerol (GGPL-III) (2-5). The frequency of antibodies to GGPL-III is significantly higher in sera from HIV-1 infected people than from HIV-1 negative healthy donors suggesting that Mycoplasma fermentans is an influence in the pathogenicity of acquired immunodeficiency syndrome (AIDS) (2,3).

Reviews


No reviews yet

ABOUT THE COMPANY

Santa Cruz Biotechnology is a world leader in the development of products for the biomedical research market. Over the past 30+ years, the Company has focused on the ongoing development of research antibodies, siRNA and CRISPR Gene editing tools, biochemicals, labware and more recently has expanded into animal health care products. Santa Cruz Biotechnology has the highest commitment to quality and customer service.